TiumBio's Tosposertib Receives U.S. FDA Fast Track Designation, Accelerating Head and Neck Cancer Drug Development

TiumBio's immuno-oncology candidate tosposertib has received Fast Track designation from the U.S. Food and Drug Administration (FDA). After demonstrating promise in a clinical trial involving patients with recurrent or metastatic head and neck cancer, the company plans to work with regulators to refine its late-stage clinical development and regulatory approval strategy.

TiumBio announced on November 4 that the FDA had granted Fast Track designation to tosposertib in combination with Keytruda (generic name: pembrolizumab) as a first-line treatment for recurrent or metastatic head and neck cancer. The company said the designation reflects recognition of the treatment's potential to address unmet medical needs in head and neck cancer.

Fast Track is an FDA program designed to expedite the development and review of treatments for serious conditions. For designated drugs, companies can work closely with the FDA on clinical trial design and regulatory approval strategies. If they meet the requirements, they may also apply for rolling review, accelerated approval, and priority review.

Tosposertib is an oral small-molecule dual inhibitor that simultaneously blocks transforming growth factor beta (TGF-β) and vascular endothelial growth factor receptor 2 (VEGFR2), which are involved in immune suppression and tumor growth in the tumor microenvironment. It is being developed to enhance the therapeutic effects of immuno-oncology drugs such as Keytruda by promoting the infiltration of immune cells and anticancer drugs into tumors.

Clinical results have also been reported. According to Phase 2a data presented at the American Society of Clinical Oncology (ASCO) meeting this year, among 12 patients receiving first-line treatment for recurrent or metastatic head and neck cancer, one achieved a complete response (CR) and eight achieved a partial response (PR). The objective response rate (ORR) was 75%. Median progression-free survival (mPFS) was 10.9 months, while median overall survival (mOS) had not been reached at the time of analysis.

Following the Fast Track designation, TiumBio plans to work with the FDA to refine the design of follow-up clinical trials and its regulatory approval strategy. It also plans to accelerate preparations for a global Phase 2b trial and partnering efforts with overseas pharmaceutical companies.

Kim Huntaek, CEO of TiumBio, said, "Building on tosposertib's differentiated clinical profile, we have secured an important regulatory milestone with the FDA Fast Track designation. This is significant because it means we have moved beyond an early-stage clinical pipeline and entered a phase of accelerated global development."

He added, "We will work with the FDA and regulatory authorities in each country to efficiently advance late-stage clinical development and our regulatory approval strategy. Building on the potential to become a best-in-class treatment, we will also step up global clinical development and partnering."

This content was produced with the assistance of AI translation services.